FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885171423> ?p ?o ?g. }

• W2885171423 abstract "Introduction: Regulatory T cells (Tregs) and conventional T cells (Tconvs) are differentially regulated by PI3K isoforms. Tregs are dependent on the PI3Kδ isoform, whereas Tconvs are regulated by PI3Kα and PI3Kβ instead of PI3Kδ as a complementary pathway. Moreover, recent reports have indicated that DNA-PK inhibition reduced Tregs maintenance and function by blocking phosphorylation of Nr4a. Idelalisib, which is an approved PI3Kδ inhibitor, was shown to reduce the number of suppressive Tregs in the peripheral blood of chronic lymphocytic leukemia patients in duration- and patient age-dependent manners. As BR101801 is a first-in-class dual target inhibitor of DNA-PK and PI3Kδ, the efficacy of BR101801 as a candidate for cancer immunotherapy is presented in this study. Methods: BALB/c mice were subcutaneously inoculated into the abdomen on day 0 with 5x10 4 4T1 cells. BR101801 (50 mg/kg, once daily) or vehicle was administered by oral gavage from day -1. On day 30, mice were sacrificed, after which tumor tissue and spleen were extracted for ex vivo analysis. Human CD3+ lymphocytes were isolated from PBMCs using positive selection on magnetic beads. CD3+ lymphocytes stimulation was achieved with an anti-CD3/CD28 T cell activator. FACS analysis was performed using antibodies (CD4, CD25, Foxp3, PD-1, CTLA-4). Results: Administration of BR101801 led to significant suppression of 4T1 tumor growth (TGI : 50.48%) based on a similar pattern as the positive control PI3Kδ inhibitor (PI-3065). Interestingly, 4T1 cells did not express PI3Kδ at a detectable level. Indeed, BR101801 did not affect the growth of 4T1 cells up to 10 μM in vitro. These results mean that BR101801 induces immune-mediated tumor regression without a direct cytotoxic effect on 4T1 cells. Ex vivo analysis of the spleen showed that the population of Tregs decreased while that of CD8 lymphocytes increased upon BR101801 treatment, reciprocally. Immuno-oncological activity was confirmed in human PBMCs. BR101801 did not influence the viability of CD3+ lymphocytes and CD4+ lymphocytes but specifically decreased the population of Tregs. In addition, PD-1 and CTLA-4 expression in Tregs was reduced in a dose-dependent manner, and the results were better than those obtained using idelalisib and TGR-1202. Furthermore, the remaining effect of BR101801 was confirmed to be effective even up to 24 hours after drug removal. Conclusions: BR101801 has immunogenic potential to alter the balance of immune tolerance to anti-tumor immunity by encouraging antigen exposure, disrupting Tregs, and boosting CD8 cells. Therefore, this study suggests the potential of BR101801 to be used as a first chemical immune checkpoint inhibitor. Citation Format: Byeongwook Jeon, Jin Sang Wang, Baek kyung Kim, Bo Ram Lee, Mi kwon Son, Yeon seo Choi, Nam-Hoon Kim, Jayhyuk Myung, Dal-Hyun Kim. BR101801, a first-in-class dual target inhibitor of DNA protein kinase (DNA-PK) and phosphoinositide 3-kinase delta (PI3Kδ), triggers antitumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1939." @default.
• W2885171423 created "2018-08-22" @default.
• W2885171423 creator A5005262413 @default.
• W2885171423 creator A5008014896 @default.
• W2885171423 creator A5008384132 @default.
• W2885171423 creator A5011327006 @default.
• W2885171423 creator A5023451351 @default.
• W2885171423 creator A5028985434 @default.
• W2885171423 creator A5055620313 @default.
• W2885171423 creator A5062995205 @default.
• W2885171423 creator A5065227862 @default.
• W2885171423 date "2018-07-01" @default.
• W2885171423 modified "2023-09-25" @default.
• W2885171423 title "Abstract 1939: BR101801, a first-in-class dual target inhibitor of DNA protein kinase (DNA-PK) and phosphoinositide 3-kinase delta (PI3Kδ), triggers antitumor immunity" @default.
• W2885171423 doi "https://doi.org/10.1158/1538-7445.am2018-1939" @default.
• W2885171423 hasPublicationYear "2018" @default.
• W2885171423 type Work @default.
• W2885171423 sameAs 2885171423 @default.
• W2885171423 citedByCount "1" @default.
• W2885171423 countsByYear W28851714232022 @default.
• W2885171423 crossrefType "proceedings-article" @default.
• W2885171423 hasAuthorship W2885171423A5005262413 @default.
• W2885171423 hasAuthorship W2885171423A5008014896 @default.
• W2885171423 hasAuthorship W2885171423A5008384132 @default.
• W2885171423 hasAuthorship W2885171423A5011327006 @default.
• W2885171423 hasAuthorship W2885171423A5023451351 @default.
• W2885171423 hasAuthorship W2885171423A5028985434 @default.
• W2885171423 hasAuthorship W2885171423A5055620313 @default.
• W2885171423 hasAuthorship W2885171423A5062995205 @default.
• W2885171423 hasAuthorship W2885171423A5065227862 @default.
• W2885171423 hasConcept C148125776 @default.
• W2885171423 hasConcept C153911025 @default.
• W2885171423 hasConcept C203014093 @default.
• W2885171423 hasConcept C2776090121 @default.
• W2885171423 hasConcept C2779727006 @default.
• W2885171423 hasConcept C502942594 @default.
• W2885171423 hasConcept C62478195 @default.
• W2885171423 hasConcept C79484868 @default.
• W2885171423 hasConcept C86554907 @default.
• W2885171423 hasConcept C86803240 @default.
• W2885171423 hasConcept C8891405 @default.
• W2885171423 hasConcept C95444343 @default.
• W2885171423 hasConceptScore W2885171423C148125776 @default.
• W2885171423 hasConceptScore W2885171423C153911025 @default.
• W2885171423 hasConceptScore W2885171423C203014093 @default.
• W2885171423 hasConceptScore W2885171423C2776090121 @default.
• W2885171423 hasConceptScore W2885171423C2779727006 @default.
• W2885171423 hasConceptScore W2885171423C502942594 @default.
• W2885171423 hasConceptScore W2885171423C62478195 @default.
• W2885171423 hasConceptScore W2885171423C79484868 @default.
• W2885171423 hasConceptScore W2885171423C86554907 @default.
• W2885171423 hasConceptScore W2885171423C86803240 @default.
• W2885171423 hasConceptScore W2885171423C8891405 @default.
• W2885171423 hasConceptScore W2885171423C95444343 @default.
• W2885171423 hasLocation W28851714231 @default.
• W2885171423 hasOpenAccess W2885171423 @default.
• W2885171423 hasPrimaryLocation W28851714231 @default.
• W2885171423 hasRelatedWork W1525304663 @default.
• W2885171423 hasRelatedWork W1658273211 @default.
• W2885171423 hasRelatedWork W1920268088 @default.
• W2885171423 hasRelatedWork W2088662624 @default.
• W2885171423 hasRelatedWork W2100083914 @default.
• W2885171423 hasRelatedWork W2109388378 @default.
• W2885171423 hasRelatedWork W2141569204 @default.
• W2885171423 hasRelatedWork W2155394988 @default.
• W2885171423 hasRelatedWork W2374541921 @default.
• W2885171423 hasRelatedWork W3133948578 @default.
• W2885171423 isParatext "false" @default.
• W2885171423 isRetracted "false" @default.
• W2885171423 magId "2885171423" @default.
• W2885171423 workType "article" @default.